Tiziana's Intranasal Foralumab Shows Consistent Neuroinflammation Reduction in MSA Patients
Event summary
- Tiziana reported a 34% reduction in standardized uptake value (SUV) and 26% reduction in SUVR in the brain of the third MSA patient treated with intranasal foralumab.
- Results are consistent with previous patients, showing up to 35% reduction in SUV and 24% reduction in SUVR.
- Tarun Singhal from Brigham and Women’s Hospital noted the consistency of PET findings across patients as encouraging.
- Tiziana plans to continue evaluating intranasal foralumab in additional MSA patients.
The big picture
Tiziana's consistent results with intranasal foralumab in reducing neuroinflammation in MSA patients highlight the potential of its novel mucosal tolerance mechanism. This approach could differentiate Tiziana in the competitive landscape of neurodegenerative disease treatments, particularly as it seeks to address conditions like multiple sclerosis and Alzheimer’s disease where current options are limited.
What we're watching
- Clinical Validation
- Whether the consistent PET scan results will translate into meaningful clinical outcomes for MSA patients.
- Regulatory Pathway
- The pace at which Tiziana can advance intranasal foralumab through further trials and potential regulatory approvals.
- Market Differentiation
- How Tiziana positions intranasal foralumab against existing treatments for neurodegenerative diseases.
Related topics